132 related articles for article (PubMed ID: 38913003)
1. Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials.
Verma S; Butler J; Borlaug BA; Davies M; Kitzman DW; Shah SJ; Petrie MC; Barros E; Rönnbäck C; Vestergaard LS; Schou M; Ezekowitz JA; Sharma K; Patel S; Chinnakondepalli KM; Kosiborod MN;
J Am Coll Cardiol; 2024 Jun; ():. PubMed ID: 38913003
[TBL] [Abstract][Full Text] [Related]
2. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.
Butler J; Shah SJ; Petrie MC; Borlaug BA; Abildstrøm SZ; Davies MJ; Hovingh GK; Kitzman DW; Møller DV; Verma S; Einfeldt MN; Lindegaard ML; Rasmussen S; Abhayaratna W; Ahmed FZ; Ben-Gal T; Chopra V; Ezekowitz JA; Fu M; Ito H; Lelonek M; Melenovský V; Merkely B; Núñez J; Perna E; Schou M; Senni M; Sharma K; van der Meer P; Von Lewinski D; Wolf D; Kosiborod MN;
Lancet; 2024 Apr; 403(10437):1635-1648. PubMed ID: 38599221
[TBL] [Abstract][Full Text] [Related]
3. Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Program.
Schou M; Petrie MC; Borlaug BA; Butler J; Davies MJ; Kitzman DW; Shah SJ; Verma S; Patel S; Chinnakondepalli KM; Harring S; Abildstrøm SZ; Liisberg K; Kosiborod MN;
J Am Coll Cardiol; 2024 Jun; ():. PubMed ID: 38913004
[TBL] [Abstract][Full Text] [Related]
4. Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial.
Kosiborod MN; Verma S; Borlaug BA; Butler J; Davies MJ; Jon Jensen T; Rasmussen S; Erlang Marstrand P; Petrie MC; Shah SJ; Ito H; Schou M; Melenovský V; Abhayaratna W; Kitzman DW;
Circulation; 2024 Jan; 149(3):204-216. PubMed ID: 37952180
[TBL] [Abstract][Full Text] [Related]
5. Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype.
Kosiborod MN; Abildstrøm SZ; Borlaug BA; Butler J; Christensen L; Davies M; Hovingh KG; Kitzman DW; Lindegaard ML; Møller DV; Shah SJ; Treppendahl MB; Verma S; Petrie MC
JACC Heart Fail; 2023 Aug; 11(8 Pt 1):1000-1010. PubMed ID: 37294245
[TBL] [Abstract][Full Text] [Related]
6. Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction.
Butler J; Abildstrøm SZ; Borlaug BA; Davies MJ; Kitzman DW; Petrie MC; Shah SJ; Verma S; Abhayaratna WP; Chopra V; Ezekowitz JA; Fu M; Ito H; Lelonek M; Núñez J; Perna E; Schou M; Senni M; van der Meer P; von Lewinski D; Wolf D; Altschul RL; Rasmussen S; Kosiborod MN
J Am Coll Cardiol; 2023 Nov; 82(22):2087-2096. PubMed ID: 37993201
[TBL] [Abstract][Full Text] [Related]
7. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial.
Borlaug BA; Kitzman DW; Davies MJ; Rasmussen S; Barros E; Butler J; Einfeldt MN; Hovingh GK; Møller DV; Petrie MC; Shah SJ; Verma S; Abhayaratna W; Ahmed FZ; Chopra V; Ezekowitz J; Fu M; Ito H; Lelonek M; Melenovsky V; Núñez J; Perna E; Schou M; Senni M; van der Meer P; Von Lewinski D; Wolf D; Kosiborod MN
Nat Med; 2023 Sep; 29(9):2358-2365. PubMed ID: 37635157
[TBL] [Abstract][Full Text] [Related]
8. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
Kosiborod MN; Abildstrøm SZ; Borlaug BA; Butler J; Rasmussen S; Davies M; Hovingh GK; Kitzman DW; Lindegaard ML; Møller DV; Shah SJ; Treppendahl MB; Verma S; Abhayaratna W; Ahmed FZ; Chopra V; Ezekowitz J; Fu M; Ito H; Lelonek M; Melenovsky V; Merkely B; Núñez J; Perna E; Schou M; Senni M; Sharma K; Van der Meer P; von Lewinski D; Wolf D; Petrie MC;
N Engl J Med; 2023 Sep; 389(12):1069-1084. PubMed ID: 37622681
[TBL] [Abstract][Full Text] [Related]
9. Semaglutide and Diuretic Use in Obesity-Related Heart Failure with Preserved Ejection Fraction: A Pooled Analysis of the STEP-HFpEF and STEP-HFpEF-DM trials.
Shah SJ; Sharma K; Borlaug BA; Butler J; Davies M; Kitzman DW; Petrie MC; Verma S; Patel S; Chinnakondepalli KM; Einfeldt MN; Jensen TJ; Rasmussen S; Asleh R; Ben-Gal T; Kosiborod MN
Eur Heart J; 2024 May; ():. PubMed ID: 38739118
[TBL] [Abstract][Full Text] [Related]
10. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
Kosiborod MN; Petrie MC; Borlaug BA; Butler J; Davies MJ; Hovingh GK; Kitzman DW; Møller DV; Treppendahl MB; Verma S; Jensen TJ; Liisberg K; Lindegaard ML; Abhayaratna W; Ahmed FZ; Ben-Gal T; Chopra V; Ezekowitz JA; Fu M; Ito H; Lelonek M; Melenovský V; Merkely B; Núñez J; Perna E; Schou M; Senni M; Sharma K; van der Meer P; Von Lewinski D; Wolf D; Shah SJ;
N Engl J Med; 2024 Apr; 390(15):1394-1407. PubMed ID: 38587233
[TBL] [Abstract][Full Text] [Related]
11. Semaglutide and NT-proBNP in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program.
Petrie MC; Borlaug BA; Butler J; Davies MJ; Kitzman DW; Shah SJ; Verma S; Jensen TJ; Einfeldt MN; Liisberg K; Perna E; Sharma K; Ezekowitz JA; Fu M; Melenovský V; Ito H; Lelonek M; Kosiborod MN;
J Am Coll Cardiol; 2024 Jul; 84(1):27-40. PubMed ID: 38819334
[TBL] [Abstract][Full Text] [Related]
12. Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials.
Nassif ME; Windsor SL; Gosch K; Borlaug BA; Husain M; Inzucchi SE; Kitzman DW; McGuire DK; Pitt B; Scirica BM; Shah SJ; Umpierrez G; Austin BA; Lamba S; Khumri T; Sharma K; Kosiborod MN
Circ Heart Fail; 2023 Jul; 16(7):e009837. PubMed ID: 37203441
[TBL] [Abstract][Full Text] [Related]
13. Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials.
McMurray JJV; Docherty KF; de Boer RA; Hammarstedt A; Kitzman DW; Kosiborod MN; Maria Langkilde A; Reicher B; Senni M; Shah SJ; Wilderäng U; Verma S; Solomon SD
Circulation; 2024 Mar; 149(11):825-838. PubMed ID: 38059368
[TBL] [Abstract][Full Text] [Related]
14. Baseline characteristics of patients in the PARALLAX trial: insights into quality of life and exercise capacity in heart failure with preserved ejection fraction.
Shah SJ; Cowie MR; Wachter R; Szecsödy P; Shi V; Ibram G; Hu M; Zhao Z; Gong J; Pieske B
Eur J Heart Fail; 2021 Sep; 23(9):1541-1551. PubMed ID: 34170062
[TBL] [Abstract][Full Text] [Related]
15. Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction.
Kosiborod MN; Bhatt AS; Claggett BL; Vaduganathan M; Kulac IJ; Lam CSP; Hernandez AF; Martinez FA; Inzucchi SE; Shah SJ; de Boer RA; Jhund PS; Desai AS; Fang JC; Han Y; Comin-Colet J; Vardeny O; Lindholm D; Wilderäng U; Bengtsson O; McMurray JJV; Solomon SD
J Am Coll Cardiol; 2023 Feb; 81(5):460-473. PubMed ID: 36526515
[TBL] [Abstract][Full Text] [Related]
16. Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.
Chandra A; Vaduganathan M; Lewis EF; Claggett BL; Rizkala AR; Wang W; Lefkowitz MP; Shi VC; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; McMurray JJV; Solomon SD;
JACC Heart Fail; 2019 Oct; 7(10):862-874. PubMed ID: 31302043
[TBL] [Abstract][Full Text] [Related]
17. Rehabilitation Intervention in Older Patients With Acute Heart Failure With Preserved Versus Reduced Ejection Fraction.
Mentz RJ; Whellan DJ; Reeves GR; Pastva AM; Duncan P; Upadhya B; Nelson MB; Chen H; Reed SD; Rosenberg PB; Bertoni AG; O'Connor CM; Kitzman DW
JACC Heart Fail; 2021 Oct; 9(10):747-757. PubMed ID: 34246602
[TBL] [Abstract][Full Text] [Related]
18. Health status across major subgroups of patients with heart failure and preserved ejection fraction.
Siddiqi TJ; Anker SD; Filippatos G; Ferreira JP; Pocock SJ; Böhm M; Brueckmann M; Chopra VK; Iwata T; Januzzi J; Piña IL; Ponikowski P; Senni M; Vedin O; Verma S; Zhang Y; Zannad F; Packer M; Butler J
Eur J Heart Fail; 2023 Sep; 25(9):1623-1631. PubMed ID: 36974746
[TBL] [Abstract][Full Text] [Related]
19. Patient-Reported Frailty and Functional Status in Heart Failure With Preserved Ejection Fraction: Insights From VITALITY-HFpEF.
Kaul P; Rathwell S; Lam CSP; Westerhout CM; Spertus JA; Anstrom KJ; Blaustein RO; Ezekowitz JA; Pieske B; Roessig L; Butler J; Armstrong PW;
JACC Heart Fail; 2023 Apr; 11(4):392-403. PubMed ID: 36881394
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of semaglutide in patients with heart failure with preserved ejection fraction and obesity.
Rehman A; Saidullah S; Asad M; Gondal UR; Ashraf A; Khan MF; Akhtar W; Mehmoodi A; Malik J
Clin Cardiol; 2024 May; 47(5):e24283. PubMed ID: 38767042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]